{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:53:38Z","timestamp":1790499218842,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["R14066FF"],"award-info":[{"award-number":["R14066FF"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS103529"],"award-info":[{"award-number":["R01 NS103529"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS098813"],"award-info":[{"award-number":["R01 NS098813"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Study Objectives<\/jats:title>\n                  <jats:p>Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness in other central hypersomnolence disorders, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), is currently unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eleven biogenic amines including the monoaminergic neurotransmitters and their metabolites and five trace amines were measured in the cerebrospinal fluid (CSF) of 94 drug-free subjects evaluated at the French National Reference Center for Narcolepsy: 39 NT1(orexin-deficient) patients, 31 patients with objective sleepiness non orexin-deficient (NT2 and IH), and 24 patients without objective sleepiness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Three trace amines were undetectable in the sample: tryptamine, octopamine, and 3-iodothyronamine. No significant differences were found among the three groups for quantified monoamines and their metabolites in crude and adjusted models; however, CSF 5-hydroxyindoleacetic acid (5-HIAA) levels tended to increase in NT1 compared to other patients after adjustment. Most of the biomarkers were not associated with ORX-A levels, clinical or neurophysiological parameters, but a few biomarkers (e.g. 3-methoxy-4-hydroxyphenylglycol and norepinephrine) correlated with daytime sleepiness and high rapid eye movement (REM) sleep propensity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found no striking differences among CSF monoamines, their metabolites and trace amine levels, and few associations between them and key clinical or neurophysiological parameters in NT1, NT2\/IH, and patients without objective sleepiness. Although mostly negative, these findings are a significant contribution to our understanding of the neurobiology of hypersomnolence in these disorders that remain mysterious and deserve further exploration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/sleep\/zsab012","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T18:04:24Z","timestamp":1611252264000},"source":"Crossref","is-referenced-by-count":32,"title":["Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence"],"prefix":"10.1093","volume":"44","author":[{"given":"Lucie","family":"Barateau","sequence":"first","affiliation":[{"name":"Sleep\u2013Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier , Montpellier , France"},{"name":"National Reference Network for Narcolepsy, CHU Montpellier , Montpellier , France"},{"name":"INM, University of Montpellier, INSERM , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-7590","authenticated-orcid":false,"given":"Isabelle","family":"Jaussent","sequence":"additional","affiliation":[{"name":"INM, University of Montpellier, INSERM , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Roeser","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, South San Francisco , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ciardiello","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, South San Francisco , San Francisco, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-0094","authenticated-orcid":false,"given":"Thomas S","family":"Kilduff","sequence":"additional","affiliation":[{"name":"Center for Neuroscience, Biosciences Division, SRI International , Menlo Park, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0683-6506","authenticated-orcid":false,"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[{"name":"Sleep\u2013Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier , Montpellier , France"},{"name":"National Reference Network for Narcolepsy, CHU Montpellier , Montpellier , France"},{"name":"INM, University of Montpellier, INSERM , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"issue":"1","key":"2022080922480599000_CIT0001","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"2022080922480599000_CIT0002","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell."},{"issue":"9","key":"2022080922480599000_CIT0003","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med."},{"issue":"3","key":"2022080922480599000_CIT0004","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron."},{"issue":"4","key":"2022080922480599000_CIT0005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell."},{"issue":"2","key":"2022080922480599000_CIT0006","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron."},{"issue":"19","key":"2022080922480599000_CIT0007","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1523\/JNEUROSCI.0073-14.2014","article-title":"Conditional ablation of orexin\/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function","volume":"34","author":"Tabuchi","year":"2014","journal-title":"J Neurosci."},{"key":"2022080922480599000_CIT0008","article-title":"Animal models of narcolepsy and the hypocretin\/orexin system: past, present, and future","author":"Tisdale","year":"2020","journal-title":"Sleep."},{"key":"2022080922480599000_CIT0009","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.conb.2017.03.021","article-title":"Wake-sleep circuitry: an overview","volume":"44","author":"Saper","year":"2017","journal-title":"Curr Opin Neurobiol."},{"issue":"11","key":"2022080922480599000_CIT0010","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1212\/WNL.32.11.1299","article-title":"Narcolepsy and idiopthic hypersomnia: biogenic amines and related compounds in CSF","volume":"32","author":"Montplaisir","year":"1982","journal-title":"Neurology."},{"issue":"3","key":"2022080922480599000_CIT0011","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ana.410130306","article-title":"Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia","volume":"13","author":"Faull","year":"1983","journal-title":"Ann Neurol."},{"issue":"1 Pt 2","key":"2022080922480599000_CIT0012","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/sleep\/9.1.246","article-title":"Monoamine interactions in narcolepsy and hypersomnia: a preliminary report","volume":"9","author":"Faull","year":"1986","journal-title":"Sleep."},{"issue":"4","key":"2022080922480599000_CIT0013","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2869.2010.00819.x","article-title":"Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin","volume":"19","author":"Bassetti","year":"2010","journal-title":"J Sleep Res."},{"issue":"10","key":"2022080922480599000_CIT0014","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.5665\/sleep.2114","article-title":"Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions","volume":"35","author":"Dauvilliers","year":"2012","journal-title":"Sleep."},{"issue":"11","key":"2022080922480599000_CIT0015","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaa095","article-title":"Metabolome analysis using cerebrospinal fluid from narcolepsy type 1 patients","volume":"43","author":"Shimada","year":"2020","journal-title":"Sleep."},{"issue":"2","key":"2022080922480599000_CIT0016","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/sleep\/32.2.181","article-title":"CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome","volume":"32","author":"Kanbayashi","year":"2009","journal-title":"Sleep."},{"issue":"2","key":"2022080922480599000_CIT0017","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/sleep\/32.2.175","article-title":"Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls","volume":"32","author":"Nishino","year":"2009","journal-title":"Sleep."},{"issue":"2","key":"2022080922480599000_CIT0018","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ana.24710","article-title":"Absence of GABA-A receptor potentiation in central hypersomnolence disorders","volume":"80","author":"Dauvilliers","year":"2016","journal-title":"Ann Neurol"},{"issue":"161","key":"2022080922480599000_CIT0019","doi-asserted-by":"crossref","first-page":"161ra151","DOI":"10.1126\/scitranslmed.3004685","article-title":"Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors","volume":"4","author":"Rye","year":"2012","journal-title":"Sci Transl Med."},{"issue":"3","key":"2022080922480599000_CIT0020","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/jpet.107.132647","article-title":"Trace amine-associated receptor 1 modulates dopaminergic activity","volume":"324","author":"Lindemann","year":"2008","journal-title":"J Pharmacol Exp Ther."},{"issue":"11","key":"2022080922480599000_CIT0021","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.biopsych.2012.05.014","article-title":"Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics","volume":"72","author":"Revel","year":"2012","journal-title":"Biol Psychiatry."},{"issue":"5","key":"2022080922480599000_CIT0022","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/mp.2012.57","article-title":"A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight","volume":"18","author":"Revel","year":"2013","journal-title":"Mol Psychiatry."},{"issue":"6","key":"2022080922480599000_CIT0023","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep."},{"key":"2022080922480599000_CIT0024","article-title":"The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications","author":"Iber"},{"key":"2022080922480599000_CIT0025","volume-title":"ICSD-3: International Classification of Sleep Disorders","author":"AASM: American Academy of Sleep Medicine","year":"2014","edition":"3rd ed."},{"issue":"2","key":"2022080922480599000_CIT0026","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.25141","article-title":"Alternative diagnostic criteria for idiopathic hypersomnia: a 32-hour protocol","volume":"83","author":"Evangelista","year":"2018","journal-title":"Ann Neurol."},{"issue":"4","key":"2022080922480599000_CIT0027","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing\u2013when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J Clin Epidemiol."},{"issue":"4","key":"2022080922480599000_CIT0028","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuron.2017.01.014","article-title":"Neural circuitry of wakefulness and sleep","volume":"93","author":"Scammell","year":"2017","journal-title":"Neuron."},{"issue":"14","key":"2022080922480599000_CIT0029","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/0024-3205(85)90242-5","article-title":"Correlations between aminergic metabolites simultaneously obtained from human CSF and brain","volume":"37","author":"Stanley","year":"1985","journal-title":"Life Sci."},{"issue":"2","key":"2022080922480599000_CIT0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","article-title":"The neurobiological basis of narcolepsy","volume":"20","author":"Mahoney","year":"2019","journal-title":"Nat Rev Neurosci."},{"issue":"10","key":"2022080922480599000_CIT0031","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nrneurol.2015.172","article-title":"Monoamine neurotransmitter disorders\u2014clinical advances and future perspectives","volume":"11","author":"Ng","year":"2015","journal-title":"Nat Rev Neurol."},{"issue":"3","key":"2022080922480599000_CIT0032","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/pr.117.015305","article-title":"Trace amines and their receptors","volume":"70","author":"Gainetdinov","year":"2018","journal-title":"Pharmacol Rev."},{"issue":"6","key":"2022080922480599000_CIT0033","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/npp.2016.216","article-title":"Trace amine-associated receptor 1 regulates wakefulness and EEG spectral composition","volume":"42","author":"Schwartz","year":"2017","journal-title":"Neuropsychopharmacology."},{"issue":"8","key":"2022080922480599000_CIT0034","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41386-019-0386-8","article-title":"Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques","volume":"44","author":"Goonawardena","year":"2019","journal-title":"Neuropsychopharmacology."},{"issue":"9","key":"2022080922480599000_CIT0035","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.biopsych.2016.10.012","article-title":"Trace amine-associated receptor 1 agonists as narcolepsy therapeutics","volume":"82","author":"Black","year":"2017","journal-title":"Biol Psychiatry."},{"key":"2022080922480599000_CIT0036","doi-asserted-by":"crossref","first-page":"101326","DOI":"10.1016\/j.smrv.2020.101326","article-title":"Reply to Maski K et al. commentary on diagnosis of central disorders of hypersomnolence: challenges in defining central disorders of hypersomnolence","volume":"52","author":"Lammers","year":"2020","journal-title":"Sleep Med Rev."},{"issue":"4","key":"2022080922480599000_CIT0037","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.smrv.2010.11.003","article-title":"Serotonin control of sleep\u2013wake behavior","volume":"15","author":"Monti","year":"2011","journal-title":"Sleep Med Rev."},{"issue":"2","key":"2022080922480599000_CIT0038","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00001756-200302100-00015","article-title":"Altered rapid eye movement sleep timing in serotonin transporter knockout mice","volume":"14","author":"Wisor","year":"2003","journal-title":"Neuroreport."},{"key":"2022080922480599000_CIT0039","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.smrv.2018.09.006","article-title":"Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy","volume":"43","author":"Szabo","year":"2019","journal-title":"Sleep Med Rev."},{"issue":"9","key":"2022080922480599000_CIT0040","first-page":"955","article-title":"Disrupted nighttime sleep in narcolepsy","volume":"9","author":"Roth","year":"2013","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med."},{"issue":"2","key":"2022080922480599000_CIT0041","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1172\/JCI71017","article-title":"Orexin neurons suppress narcolepsy via 2 distinct efferent pathways","volume":"124","author":"Hasegawa","year":"2014","journal-title":"J Clin Invest."},{"issue":"8","key":"2022080922480599000_CIT0042","doi-asserted-by":"crossref","first-page":"789","DOI":"10.5664\/jcsm.2922","article-title":"Test\u2013retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia","volume":"9","author":"Trotti","year":"2013","journal-title":"J Clin Sleep Med."},{"issue":"12","key":"2022080922480599000_CIT0043","doi-asserted-by":"crossref","first-page":"zsx164","DOI":"10.1093\/sleep\/zsx164","article-title":"Test\u2013retest reliability of the multiple sleep latency test in central disorders of hypersomnolence","volume":"40","author":"Lopez","year":"2017","journal-title":"Sleep."}],"container-title":["Sleep"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsab012\/36510413\/zsab012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/44\/7\/zsab012\/45297618\/zsab012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/44\/7\/zsab012\/45297618\/zsab012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T22:49:01Z","timestamp":1660085341000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsab012\/6105273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,1,21]]},"published-print":{"date-parts":[[2021,7,9]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsab012","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,1,21]]},"article-number":"zsab012"}}